For EGFR TKI combined with antiangiogenic therapy, AfaBev‐CS study was a randomized, open‐label, multicenter Phase II trial comparing afatinib plus bevacizumab versus afatinib alone as first‐line treatment for EGFR‐mutated advanced NSCLC [6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.